Keywords
hyperthermic intraperitoneal chemotherapy (HIPEC)
peritoneal metastasis
peritoneal carcinomatosis
GASTRIPEC trial
Abstract
The incidence of synchronous or metachronous peritoneal metastases (PM) in patients with locally advanced gastric cancer is high, and associated with a poor prognosis. The recommended therapeutic option for these patients is systemic chemotherapy and leads to a median of 7-8 months. However, new approaches like cytoreductive surgery and hyperthermic intraperitoneal chemotherapy might help to improve the median survival in selected patients.
Indications, patient selection and the choice of the chemotherapeutic agent are described in this manuscript, as well as an overview of the most recent literature about this topic.
References
1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Ferlay J, Soerjomataram I, Dikshit R, et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386.
3. Ajani JA, Bentrem DJ, Besh S, et al.: Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013;11:531-46.
4. Okines A, Verheij M, Allum W, et al.: Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50-4.
5. Chang JS, Kim KH, Keum KC, et al.: Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. J Surg Oncol. 2016;114:859-64.
6. Seyfried F, von Rahden BH, Miras AD, et al.: Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin--a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer 2015;15:73.
7. Yonemura Y, Endou Y, Sasaki T, et al.: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36:1131-8.
8. Roviello F, Caruso S, Neri A, et al.: Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39:1309-16.
9. Yan TD, Black D, Sugarbaker PH, et al.: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702-13.
10. Mi DH, Li Z, Yang KH, et al.: Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia 2013;29:156-67.
11. Sun J, Song Y, Wang Z, et al.: Clinical significance of palliative gastrectomy on the survival of patients with incurable advanced gastric cancer: a systematic review and meta-analysis. BMC Cancer 2013;13:577.
12. Yan TD, Edwards G, Alderman R, et al.: Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma-a prospective study of 70 consecutive cases. Ann Surg Oncol. 2007;14:515-25.
13. Coccolini F, Cotte E, Glehen O, et al.: Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40:12-26.
14. Van Der Speeten K, Stuart OA, Sugarbaker PH: Pharmacology of perioperative intraperitoneal and intravenous chemotherapy in patients with peritoneal surface malignancy. Surg Oncol Clin N Am. 22012;21:577-97.
15. Braam HJ, Schellens JH, Boot H, et al.: Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol. 2015;95:282-96.
16. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-74.
17. Glehen O, Gilly FN, Arvieux C, et al.: Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370-7.
18. Gill RS, Al-Adra DP, Nagendran J, et al.: Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol. 2011;104:692-8.
19. Rau B, Löffler M, Rau HG, et al.: Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC). J Clin Oncol. 2015;33, (abstr).
20. Al-Batran SE, Hofheinz RD, Pauligk C, et al.: Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697-708.
21. Costa WL, Jr., Coimbra FJ, Ribeiro HS, et al.: Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol. 2012;10:195.
22. Huang JY, Xu YY, Sun Z, et al.: Comparison different methods of intraoperative and intraperitoneal chemotherapy for patients with gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:4379-85.
23. Yang XJ, Huang CQ, Suo T, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-81.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2018 Authors